Soligenix Submits Type A Meeting Request To US FDA To Review Proposed Study Design For A Second Phase 3 Study Evaluating HyBryte In The Treatment Of Cutaneous T-Cell Lymphoma
Soligenix Submits Type A Meeting Request To US FDA To Review Proposed Study Design For A Second Phase 3 Study Evaluating HyBryte In The Treatment Of Cutaneous T-Cell Lymphoma
Soligenix 向美國食品藥品管理局提交了 A 類會議申請，要求審查評估Hybryte在皮膚T細胞淋巴瘤治療中的第二項3期研究的擬議研究設計
Soligenix Submits Type A Meeting Request To US FDA To Review Proposed Study Design For A Second Phase 3 Study Evaluating HyBryte In The Treatment Of Cutaneous T-Cell Lymphoma
Soligenix 向美國食品藥品管理局提交了 A 類會議申請，要求審查評估Hybryte在皮膚T細胞淋巴瘤治療中的第二項3期研究的擬議研究設計